Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in
the world. Metabolic reprogramming is considered a new hallmark of cancer, but it remains …

Systemic therapy for advanced hepatocellular carcinoma has expanded at an
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …

Although viral hepatocellular carcinoma (HCC) is declining, nonviral HCC, which often is the
end stage of nonalcoholic or alcoholic steatohepatitis (NASH, ASH), is on an upward …

Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene
and is constitutively expressed on the surface of immune cells. As a receptor and immune …

Background Numerous studies have used multi-region sampling approaches to characterize
intra-tumor heterogeneity (ITH) in hepatocellular carcinoma (HCC). However, conventional …

Hepatocellular carcinoma (HCC) is a malignant and deadly form of liver cancer with limited
treatment options. Transcatheter arterial chemoembolization, a procedure that delivers …

Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third
leading cause of cancer-related deaths globally. Hepatic arterial infusion chemotherapy …

Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited
therapeutic options and poor prognosis. In recent years, immunotherapies such as immune …

Introduction The heterogeneity of tumor immune microenvironments is a major factor in poor
prognosis among hepatocellular carcinoma (HCC) patients. Neutrophils have been …

Hepatocellular carcinoma (HCC) is one of the most common cancerous tumors and one of
the leading causes of death among cancer-related disorders. Chemotherapy is ineffective in …